SCHEMBL63287

SCHEMBL63287

O=C(NC12CCC(Cn3c1nc(C(=O)NCc1ccc(F)cc1)c(O)c3=O)OC2)OCc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.42
CYP2C9 P11712 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
ERCC1 P07992 1/20 0.36
FEN1 P39748 1/20 0.36
ERCC4 Q92889 1/20 0.36
LMNA P02545 2/20 0.35
MAPT P10636 1/20 0.35
ALDH1A1 P00352 2/20 0.35
KCNE1 P15382 1/20 0.35
CCR1 P32246 1/20 0.35
KCNQ1 P51787 1/20 0.35
GAA P10253 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CALCA P06881 1/20 0.34
AADAT Q8N5Z0 1/20 0.34
CNR2 P34972 1/20 0.34
SCD O00767 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63543 0.89 KCNH2 (0.42) KCNH2CYP2C9SMN1; SMN2L3MBTL1ERCC1
SCHEMBL62281 0.89 KCNH2 (0.42) KCNH2CYP2C9SMN1; SMN2L3MBTL1ERCC1
SCHEMBL2634243 0.89 KCNH2 (0.46) KCNH2CYP2C9SMN1; SMN2L3MBTL1ERCC1
SCHEMBL62481 0.88 KCNH2 (0.42) KCNH2CYP2C9SMN1; SMN2L3MBTL1ERCC1
SCHEMBL52850 0.86 KCNH2 (0.48) KCNH2CYP2C9SMN1; SMN2L3MBTL1ERCC1
SCHEMBL10144300 0.85 KCNH2 (0.49) KCNH2CYP2C9SMN1; SMN2L3MBTL1ERCC1
Hydrochloric Acid SCHEMBL418545 0.84 KCNH2 (0.48) KCNH2CYP2C9SMN1; SMN2L3MBTL1ERCC1
SCHEMBL63101 0.84 KCNH2 (0.43) KCNH2CYP2C9SMN1; SMN2L3MBTL1ERCC1
SCHEMBL52276 0.84 ROCK2 (0.36) SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL417610 0.83 KCNH2 (0.45) KCNH2CYP2C9SMN1; SMN2L3MBTL1ERCC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG KCNH2 3969/4885CYP2C9 602/4885SMN1; SMN2 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.